Acute myeloid leukemia (AML) is the most common leukemia in adults and is primarily diagnosed in older patients. The combination of the BCL2 inhibitor, venetoclax, with a hypomethylating agent has recently become standard of care front-line therapy for patients who are unfit for high intensity induction chemotherapy and allogeneic stem cell transplantation. However, for patients who experience disease refractoriness/relapse, second line treatment options are limited. Natural killer (NK) cells have been shown to have potent anti-tumor effects in AML may represent a potential therapeutic option for patients with progression after venetoclax-based therapy.
Details
Title
Upregulation of HLA-e drives defective natural killer cell targeting in venetoclax-resistant acute myeloid leukemia
Creator
Chandra, Daniel : Oregon Health and Science University Burns, Faith : Oregon Health and Science University Kosaka, Yoko : Oregon Health and Science University Kurtz, Stephen E. : Oregon Health and Science University Tyner, Jeffrey W. : Oregon Health and Science University Lind, Evan F. : Oregon Health and Science University Saultz, Jennifer N. : Oregon Health and Science University
Meeting Name
Research Week, Oregon Health and Science University, 2024